| Date Filed | Type | Description |
| 09/25/2019 |
GN
| BriaCell Appoints Immunology Expert, Dr. Cara L. Haymaker, to Scientific Advisory Board; BriaCell CEO to Lead Special ‘Targeted Immunotherapy' Issue in Prestigious Journals |
| 09/16/2019 |
GN
| BriaCell to Present September 19th at 2nd Annual Next Gen Immuno-Oncology Congress in Philadelphia |
| 09/09/2019 |
GN
| BriaCell Announces Closing of Upsized Non-Brokered Private Placement of $846,301.49 |
| 08/27/2019 |
GN
| BriaCell Announces Participation at the 21st Annual Global Investment Conference in New York City September 8-10, 2019 |
| 08/12/2019 |
GN
| BriaCell Appoints Richard J. Berman to Board of Directors |
| 07/23/2019 |
GN
| BriaCell Announces $350,000 Equity Investment by Board of Directors |
| 05/28/2019 |
GN
| BriaCell's Novel Technology and Clinical Data Published at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting |
| 05/14/2019 |
GN
| Merus annonce le traitement d'un premier patient en phase 1 de l'essai clinique de MCLA-145 pour des tumeurs solides avancées |
| 05/14/2019 |
GN
| Merus gibt Behandlung des ersten Patienten in seiner Phase-1-Studie zu MCLA-145 für fortgeschrittene solide Tumore bekannt |
| 05/13/2019 |
GN
| BriaCell Approves New Board of Directors and Chairman at Annual and Special Meeting of Shareholders |
| 05/09/2019 |
GN
| Merus Announces First Patient Treated in Phase 1 Clinical Trial of MCLA-145 for Advanced Solid Tumors |
| 04/02/2019 |
GN
| BriaCell Announces Clinical Trial Collaboration Agreement with Incyte |
| 04/01/2019 |
GN
| Merus and Incyte Present MCLA-145 Program Preclinical Data at the AACR Annual Meeting 2019 |
| 04/01/2019 |
GN
| Merus und Incyte präsentieren auf der AACR-Jahrestagung 2019 die präklinischen Daten des MCLA-145-Programms |
| 01/29/2019 |
GN
| Report: Developing Opportunities within Incyte, Burlington Stores, Hannon Armstrong Sustainable Infrastructure Capital, iRobot, Lear, and Menlo Therapeutics ?? Future Expectations, Projections Moving into 2019 |
| 01/08/2019 |
GN
| Merus annonce l'autorisation (IND) pour le MCLA-145 |
| 01/08/2019 |
GN
| Merus gibt Freigabe von MCLA-145 als Prüfpräparat bekannt |
| 01/07/2019 |
GN
| Merus Announces IND Clearance for MCLA-145 |
| 11/05/2018 |
GN
| Factors of Influence in 2018, Key Indicators and Opportunity within Molson Coors Brewing, Coca-Cola European Partners, Brinker International, Incyte, RPC, and Group 1 Automotive — New Research Emphasizes Economic Growth |
| 08/10/2018 |
GN
| New Research: Key Drivers of Growth for United Rentals, DISH Network, Terex, Plains Group Holdings, The Hain Celestial Group, and Incyte — Factors of Influence, Major Initiatives and Sustained Production |
| 05/01/2018 |
BW
| Incyte Reports 2018 First-Quarter Financial Results and Updates on Key Clinical Programs |
| 04/13/2018 |
BW
| Incyte to Report First Quarter Financial Results |
| 03/08/2018 |
GN
| Report: Exploring Fundamental Drivers Behind Old Republic International, NiSource, MasTec, Lincoln National, Oceaneering International, and Incyte — New Horizons, Emerging Trends, and Upcoming Developments |
| 02/15/2018 |
BW
| Incyte Reports 2017 Fourth-Quarter and Year-End Financial Results, Provides 2018 Financial Guidance and Updates on Key Clinical Programs |
| 01/31/2018 |
BW
| Incyte Updates Conference Call Time to Report Fourth Quarter and Year-End Financial Results |
| 01/24/2018 |
BW
| Incyte to Report Fourth Quarter and Year-End Financial Results |
| 12/14/2017 |
BW
| Incyte to Present at Upcoming Investor Conference |
| 11/15/2017 |
GN
| Investor Expectations to Drive Momentum within Barracuda Networks, Abraxas Petroleum, Vertex Pharmaceuticals, Incyte, Forum Energy, and S&P Global – Discovering Underlying Factors of Influence |
| 10/31/2017 |
BW
| Incyte Reports 2017 Third-Quarter Financial Results and Updates on Key Clinical Programs |
| 10/24/2017 |
BW
| Incyte to Present at Upcoming Investor Conference |
| 10/12/2017 |
BW
| Incyte to Report Third Quarter Financial Results |
| 09/19/2017 |
GN
| Merus Announces Second Quarter 2017 Financial Results and Highlights Recent Progress |
| 09/18/2017 |
GN
| Incyte Corporation (Nasdaq: INCY) to Ring The Nasdaq Stock Market Closing Bell |
| 09/09/2017 |
BW
| Progression-Free Survival Data from ECHO-202 Trial of Incyte's Epacadostat in Combination with KEYTRUDA® (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melanoma |
|